Farnesoid X receptor suppresses pancreatic cancer cell proliferation through negative regulation of matrix metalloproteinase 7

doi:10.16352/j.issn.1001-6325.2026.02.0250

Abstract

Abstract: Objective To investigate the correlation between the expression of farnesoid X receptor (FXR) and matrix metalloproteinase 7 (MMP7) in pancreatic cancer cells, and to elucidate the role of FXR in regulating pancreatic cancer cell proliferation. Methods The effects of FXR on proliferation and MMP7 expression in pancreatic cancer cells (BxPC-3, PANC-1) were evaluated by in vitro experiments (CCK-8 assay, RT-PCR and Western blot). Bioinformatics analysis using GEPIA2 was performed to assess FXR/MMP7 expression and clinical prognosis in pancreatic cancer tissues, with immunohistochemistry (IHC) validating their correlation. Results FXR activation by GW4064 significantly inhibited pancreatic cancer cell proliferation (P＜0.05) and down-regulated MMP7 mRNA and protein levels (P＜0.01); while FXR inhibition by NDB significantly increased pancreatic cancer cell proliferation (P＜0.01) and upregulated the expression of MMP7 mRNA and protein(P＜0.001,P＜0.01). Bioinformatics analysis indicated that MMP7 was highly expressed in pancreatic adenocarcinoma tissues (P＜0.05), and its high expression was significantly associated with poor patient prognosis (P＜0.05); while no statistically significant association was found between FXR and prognosis. IHC (n=16) suggested an inverse correlation between FXR and MMP7 expression (R²=0.536 9). Conclusions FXR suppresses pancreatic cancer cell proliferation by negatively regulating MMP7, suggesting the BA(bile acid)-FXR-MMP7 axis as a potential therapeutic target.

Key words: pancreatic cancer, Farnesoid X receptor(FXR), matrix metalloproteinase 7(MMP7), cell proliferation, targeted therapy

CLC Number:

R735.9

LI Zhitao, BU Xuefeng, ZHANG Yongjun, MENG Nana, XIA Leizhou. Farnesoid X receptor suppresses pancreatic cancer cell proliferation through negative regulation of matrix metalloproteinase 7[J]. Basic & Clinical Medicine, 2026, 46(2): 250-255.

References

[1]Mizrahi JD, Surana R, Valle JW, et al. Pancreatic cancer[J]. Lancet,2020, 395:2008-2020. doi: 10.1016/s0140-6736(20)30974-0.
[2]Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 4:47-53. doi: 10.1016/j.jncc.2024.01.006.
[3]Neoptolemos JP, Palmer DH, Ghaneh P, et al. Compari-son of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet, 2017, 389:1011-1024. doi: 10.1016/s0140-6736(16)32409-6.
[4]王维斌, 董良博, 赵邦博, 等. 法尼醇X受体表达与胰腺癌患者预后及病理分期相关[J]. 基础医学与临床, 2018, 38:6. doi: 10.3969/j.issn.1001-6325.2018.03.022.
[5]Fukuda A, Wang SC, Morris JP 4th, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression[J]. Cancer Cell, 2011, 19:456-469. doi: 10.1016/j.ccr.2011.03.002.
[6]Tang Z, Kang B, Li C,et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47:W556-W560. doi: 10.1093/nar/gkz430.
[7.]Del Chiaro M, Sugawara T, Karam SD,et al. Advances in the management of pancreatic cancer[J]. BMJ(Clinical research ed), 2023, 383:e073995. doi: 10.1136/bmj-2022-073995.
[8]吴佳懿, 段云捷: 局部晚期胰腺癌治疗技术的进展[J]. 中国现代普通外科进展, 2023, 26:460-462. doi: 10.3969/j.issn.1009-9905.2023.06.009.
[9]Kolbeinsson HM, Chandana S, Wright GP,et al. Pancreatic cancer: A review of current treatment and novel therapies[J]. J Inrest Surg,2023, 36:2129884. doi: 10.1080/08941939.2022.2129884.
[10] Dong X, Qi M, Cai C,et al. Farnesoid X receptor mediates macrophage-intrinsic responses to suppress colitis-induced colon cancer progression[J]. JCI Insight, 2024, 9. doi: 10.1172/jci.insight.170428.
[11]Li M, Zhang X, Lu Y,et al. The nuclear translocation of transketolase inhibits the farnesoid receptor expression by promoting the binding of HDAC3 to FXR promoter in hepatocellular carcinoma cell lines[J]. Cell Death Dis, 2020, 11:31. doi: 10.1038/s41419-020-2225-6.
[12]Jin X, Shang B, Wang J,et al. Farnesoid X receptor promotes non-small cell lung cancer metastasis by activating Jak2/STAT3 signaling via transactivation of IL-6ST and IL-6 genes[J]. Cell Death Dis, 2024, 15:148. doi: 10.1038/s41419-024-06495-y.
[13]Alba J, Barcia R, Gutiérrez-Berzal J,et al. Could inhibition of metalloproteinases be used to block the process of metastasis?[J]. Cell Biochem Funct, 2022, 40:600-607. doi: 10.1002/cbf.3730.

[1]	KANG Lei, ZHU Junlan. Molecular mechanisms of selenium binding protein 1 expression regulation in cancer cells [J]. Basic & Clinical Medicine, 2025, 45(9): 1224-1228.
[2]	CHEN Lei,REN Weihao,WANG Lide. Knockdown of translocase of inner mitochondrial membrane 8A enhances gefitinib sensitivity to lung cancer cell line PC-9 [J]. Basic & Clinical Medicine, 2025, 45(8): 1073-1077.
[3]	XU Yeting, QIN Ziyi, WANG Yucheng, WU huanwen, JU Rui, GUO Lei. Correlation of oncogene c-MYC expression with mitochondrial metabolic enzyme DLAT/DLST and progression of pancreatic ductal adenocarcinoma [J]. Basic & Clinical Medicine, 2025, 45(4): 450-455.
[4]	ZHANG Yao, ZHANG Xuan, JIA Anna, ZHAN Shijia, GUO Jinxin, CHANG Yan, GUO Yongli. Olfactory domain family protein 3 promotes the proliferation of MYCN-amplified neuroblastoma cell lines in vitro [J]. Basic & Clinical Medicine, 2025, 45(2): 168-175.
[5]	LIU Fengshuo, GUAN Mei. Treatment of antibody-drug conjugates in elderly patients [J]. Basic & Clinical Medicine, 2025, 45(10): 1270-1276.
[6]	GAO Yidan, JIANG Xuehan, ZHANG Hong, YANG Peiran. Development of novel therapies targeting at dysregulated signaling pathways in pulmonary arterial hypertension [J]. Basic & Clinical Medicine, 2024, 44(8): 1088-1093.
[7]	YAO Anjun, CHEN Lingzi, JIN Huixian. Docosahexaenoic acid inhibits proliferation of human colon cancer cell line HT-29 [J]. Basic & Clinical Medicine, 2024, 44(8): 1107-1112.
[8]	CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue. Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926 [J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
[9]	ZHANG Pengju, LI Jie, ZHANG Mengdi, SUN Shaoke, XU Yinzhe. KAT8 promotes the proliferation of colorectal cancer cell lines by enhancing METTL3 expression [J]. Basic & Clinical Medicine, 2024, 44(7): 931-939.
[10]	GAO Yinjie, TONG Anli. Mechanisms of cell death and proliferation of aldosterone-producing adenoma [J]. Basic & Clinical Medicine, 2024, 44(6): 758-762.
[11]	DUAN Ran, LI Qingyuan, FENG Tong. Metabolic reprogramming in idiopathic pulmonary fibrosis [J]. Basic & Clinical Medicine, 2024, 44(6): 882-886.
[12]	WANG Tingting, XIAO Ning, LIN Dianxin, DONG Haitao. Allicin inhibits the proliferation of oral cancer cells line CAL27 [J]. Basic & Clinical Medicine, 2024, 44(5): 673-676.
[13]	JIA Anna, GUO Jinxin, ZHANG Xuan, ZHAN Shijia, YU Yongbo, GUO Yongli, CHANG Yan. Regulation of TMEFF1 on proliferation of neuroblastoma cell lines [J]. Basic & Clinical Medicine, 2024, 44(5): 637-644.
[14]	LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang. Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis [J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
[15]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.